AC Immune (NASDAQ:ACIU) Earns Buy Rating from BTIG Research

Key Points

• BTIG Research reaffirmed a “buy” rating on AC Immune and set an $8.00 price target, implying potential upside of 182.69% from the prior close.
• Analyst sentiment is generally positive: three analysts rate the stock Buy and one rates it Sell, resulting in a “Moderate Buy” consensus and an average price target of $7.50.
• AC Immune reported quarterly revenue of $18.67 million and earnings of $0.03 per share, exceeding analyst expectations, though the company remains unprofitable with a negative net margin.

AC Immune (NASDAQ:ACIU - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at BTIG Research in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $8.00 target price on the stock. BTIG Research's target price points to a potential upside of 182.69% from the company's previous close.

Other research analysts also recently issued research reports about the company. HC Wainwright reiterated a "buy" rating on shares of AC Immune in a report on Monday, August 24th. Weiss Ratings restated a "sell (e+)" rating on shares of AC Immune in a report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, AC Immune presently has an average rating of "Moderate Buy" and a consensus price target of $7.50.

AC Immune Price Performance

Shares of AC Immune stock opened at $2.83 on Wednesday. The business has a 50 day moving average of $2.55 and a 200 day moving average of $2.68. AC Immune has a 52 week low of $2.10 and a 52 week high of $4.00. The company has a market cap of $288.01 million, a PE ratio of -5.24 and a beta of 1.60. The company has a quick ratio of 1.02, a current ratio of 0.93 and a debt-to-equity ratio of 0.11.

AC Immune (NASDAQ:ACIU - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The business had revenue of $18.67 million during the quarter, compared to analyst estimates of $9.59 million. As a group, equities research analysts forecast that AC Immune will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On AC Immune

Large investors have recently bought and sold shares of the business. AXQ Capital LP bought a new stake in shares of AC Immune in the second quarter worth approximately $25,000. Dimensional Fund Advisors LP raised its stake in AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company's stock valued at $1,071,000 after buying an additional 176,701 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company's stock valued at $1,116,000 after buying an additional 30,035 shares during the period. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune SA NASDAQ: ACIU is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. Founded in 2003, the company develops precision medicines and diagnostic products designed to prevent, diagnose and treat neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and other conditions associated with misfolded proteins.

AC Immune's research is based on its SupraAntigen and Morphomer technology platforms, which are intended to identify disease-related proteins and generate therapies or diagnostic tools that target them.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.